ObjectiveTo realize the detection and drug resistance of Stenotrophomonas maltophilia (Sma) isolated from clinical samples, so as to provide evidence for preventing and treating Sam infection.MethodsClinical and laboratory data of 230 Sma strains isolated from clinical departments between 2004 and 2009 was analysed retrospectively.Results230 strains of Sma were isolated from 53 811 clinical samples, the total isolation rate was 0.43%; The annual isolation rate increased by 14fold within 6 years(from 0.06% in 2004 to 0.84% in 2009). The detection rates were high in patients in respiratory department（125 isolates,54.35%）, old patients aged ≥60 (159 isolates, 69.13%), and sputum sample (215 isolates, 93.48%). Antimicribial susceptibility test results showed that Sma was highly and multiply resistant to ampicillin, amikacin, aztreonam, gentamicin, imipenem, meropenem, cefazolin,cefoxitin, cefotaxime, cefuroxime, and cefepime, the resistant rates was between 66.20% and 100.00%; The resistant rates to minocycline, ciprofloxacin, levofloxacin, sulfamethoxazole/trimethoprim, ceftazidime, piperacillin/tazobactam and cefoperazone /sulbactam was between 0.00% and 23.08%.ConclusionThe rapid increase in isolation rate of Sma from clinical samples and multiple drugresistance to commonly used antimicrobial agents can bring about enormous difficulty to the prevention and treatment of infection, which should pay high attention .